Wungki Park1, Deukwoo Kwon2, Diana Saravia3, Amrita Desai3, Fernando Vargas3, Mohamed El Dinali3, Jessica Warsch4, Roy Elias3, Young Kwang Chae5, Dae Won Kim6, Sean Warsch3, Adrian Ishkanian7, Chukwuemeka Ikpeazu3, Raja Mudad3, Gilberto Lopes3, Mohammad Jahanzeb3. 1. Divisions of Hematology and Medical Oncology, Departments of Medicine, Miller School of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL. Electronic address: wungkipark@gmail.com. 2. Biostatistics and Bioinformatics Core, Sylvester Comprehensive Cancer Center, Miami, FL. 3. Divisions of Hematology and Medical Oncology, Departments of Medicine, Miller School of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL. 4. Department of Radiology, Miller School of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL. 5. Developmental Therapeutics Program of Division of Hematology Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL. 6. Division of Medical Oncology, Department of Medical Oncology, Moffitt Cancer Center, Tampa, FL. 7. Department of Radiation Oncology, Miller School of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL.
Abstract
INTRODUCTION: Despite significant improvement of clinical outcomes of advanced non-small-cell lung cancer (NSCLC) patients treated with immunotherapy, our knowledge of optimal biomarkers is still limited. PATIENTS AND METHODS: We retrospectively evaluated 159 advanced NSCLC patients in our institution treated with nivolumab after disease progression during platinum-based chemotherapy. We correlated several variables with progression-free survival (PFS) to develop the immunotherapy, Sex, Eastern Cooperative Oncology Group performance status, Neutrophil-to-lymphocyte ratio (NLR), and Delta NLR (iSEND) model. We categorized patients into iSEND good, intermediate, and poor risk groups and evaluated their clinical outcomes. Performance of iSEND at 3, 6, 9, and 12 months was evaluated according to receiver operating characteristic (ROC) curves and internally validated using bootstrapping. The association of iSEND risk groups with clinical benefit was evaluated using logistic regression. RESULTS: Median follow-up was 11.5 months (95% confidence interval [CI], 9.4-13.1). There were 50 deaths and 43 with disease progression without death. PFS rates at 3, 6, 9, and 12 months were 78.4%, 63.7%, 55.3%, and 52.2% in iSEND good; 79.4%, 44.3%, 25.9%, and 19.2% in iSEND intermediate; and 65%, 25.9%, 22.8%, and 17.8% in iSEND poor. Time-dependent area under ROC curves of iSEND for PFS at 3, 6, 9, and 12 months were 0.718, 0.74, 0.746, and 0.774. The iSEND poor group was significantly associated with progressive disease at 12 ± 2 weeks (odds ratio, 9.59; 95% CI, 3.8-26.9; P < .0001). CONCLUSION: The iSEND model is an algorithmic model that can characterize clinical outcomes of advanced NSCLC patients receiving nivolumab into good, intermediate, or poor risk groups and might be useful as a predictive model if validated independently.
INTRODUCTION: Despite significant improvement of clinical outcomes of advanced non-small-cell lung cancer (NSCLC) patients treated with immunotherapy, our knowledge of optimal biomarkers is still limited. PATIENTS AND METHODS: We retrospectively evaluated 159 advanced NSCLCpatients in our institution treated with nivolumab after disease progression during platinum-based chemotherapy. We correlated several variables with progression-free survival (PFS) to develop the immunotherapy, Sex, Eastern Cooperative Oncology Group performance status, Neutrophil-to-lymphocyte ratio (NLR), and Delta NLR (iSEND) model. We categorized patients into iSEND good, intermediate, and poor risk groups and evaluated their clinical outcomes. Performance of iSEND at 3, 6, 9, and 12 months was evaluated according to receiver operating characteristic (ROC) curves and internally validated using bootstrapping. The association of iSEND risk groups with clinical benefit was evaluated using logistic regression. RESULTS: Median follow-up was 11.5 months (95% confidence interval [CI], 9.4-13.1). There were 50 deaths and 43 with disease progression without death. PFS rates at 3, 6, 9, and 12 months were 78.4%, 63.7%, 55.3%, and 52.2% in iSEND good; 79.4%, 44.3%, 25.9%, and 19.2% in iSEND intermediate; and 65%, 25.9%, 22.8%, and 17.8% in iSEND poor. Time-dependent area under ROC curves of iSEND for PFS at 3, 6, 9, and 12 months were 0.718, 0.74, 0.746, and 0.774. The iSEND poor group was significantly associated with progressive disease at 12 ± 2 weeks (odds ratio, 9.59; 95% CI, 3.8-26.9; P < .0001). CONCLUSION: The iSEND model is an algorithmic model that can characterize clinical outcomes of advanced NSCLCpatients receiving nivolumab into good, intermediate, or poor risk groups and might be useful as a predictive model if validated independently.
Authors: Giuseppe Luigi Banna; Alex Friedlaender; Marco Tagliamento; Veronica Mollica; Alessio Cortellini; Sara Elena Rebuzzi; Arsela Prelaj; Abdul Rafeh Naqash; Edouard Auclin; Lucia Garetto; Laura Mezquita; Alfredo Addeo Journal: Curr Oncol Rep Date: 2022-10-18 Impact factor: 5.945
Authors: M P Petrova; I S Donev; M A Radanova; M I Eneva; E G Dimitrova; G N Valchev; V T Minchev; M S Taushanova; M V Boneva; T S Karanikolova; R B Gencheva; G A Zhbantov; A I Ivanova; C V Timcheva; B P Pavlov; V G Megdanova; B S Robev; N V Conev Journal: Clin Exp Immunol Date: 2020-08-26 Impact factor: 4.330
Authors: Abdul Rafeh Naqash; Biagio Ricciuti; Dwight H Owen; Vaia Florou; Yukihiro Toi; Cynthia Cherry; Maida Hafiz; Andrea De Giglio; Mavish Muzaffar; Sandip H Patel; Shunichi Sugawara; Jarred Burkart; Wungki Park; Rita Chiari; Jun Sugisaka; Gregory A Otterson; Gilberto de Lima Lopes; Paul R Walker Journal: Cancer Immunol Immunother Date: 2020-03-05 Impact factor: 6.968
Authors: Giovanni Fucà; Giulia Galli; Marta Poggi; Giuseppe Lo Russo; Claudia Proto; Martina Imbimbo; Roberto Ferrara; Nicoletta Zilembo; Monica Ganzinelli; Antonio Sica; Valter Torri; Mario Paolo Colombo; Claudio Vernieri; Andrea Balsari; Filippo de Braud; Marina Chiara Garassino; Diego Signorelli Journal: ESMO Open Date: 2019-02-27
Authors: Mingjia Li; Daniel Spakowicz; Jarred Burkart; Sandip Patel; Marium Husain; Kai He; Erin M Bertino; Peter G Shields; David P Carbone; Claire F Verschraegen; Carolyn J Presley; Gregory A Otterson; Kari Kendra; Dwight H Owen Journal: J Cancer Res Clin Oncol Date: 2019-07-31 Impact factor: 4.553
Authors: D Viñal; L Gutierrez-Sainz; D Martinez; J A Garcia-Cuesta; J Pedregosa; J Villamayor; L Ostios; D Sanchez-Cabrero; O Higuera; A Pinto; N Rodriguez-Salas; E Espinosa; J de Castro; J Feliu Journal: Clin Transl Oncol Date: 2020-11-23 Impact factor: 3.405